Chamberlain University
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
, Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative metabolism (CYP 450 NT)
effect enzyme)
Potency (if noted. receptor occupancy if
noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target Symptoms: Half-Life: Notable Side Effects:
• Bipolar Disorder • Decanoate is approx. • Neuroleptic-induced
• Psychotic disorders 3 weeks deficit syndrome
• Behavioral disturbances in dementias • Oral: 12-38 hours • Akathisia
• Delirium w/ Metabolism: • Drug-induced Parkinsonism
Lorazepam • CYP1A2 • Tardive dyskinesia, Tardive dystonia
Schizophrenia • CYP2D6 • Risk of potentially irreversible
• Tics and vocal utterances in • CYP3A4 involuntary dyskinetic
Tourettes Syndrome movements may increase with
• Second line treatment of severe cumulative dose and treatment
behavior in children of duration
combative explosive • Galactorrhea, Amenorrhea
hyperexcitability • Dizziness Sedation
Potency: • Dry mouth, constipation,
• High potency first-generation urinary retention, blurred
Neurotransmitters: vision
• Blocks dopamine 2 receptors, • Decreased sweating
reducing positive symptoms of • Hypotension
psychosis and possibly combative, • Tachycardia
explosive, and hyperactive behaviors • Hypertension
• Blocks dopamine 2 receptors in the • Weight gain
nigrostriatal pathway, improving
tics and other symptoms in
Tourette’s
syndrome.
NR 546 / NR546
Week 3
Antipsychotics Table
Course: Advanced Pharmacology
, Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative metabolism (CYP 450 NT)
effect enzyme)
Potency (if noted. receptor occupancy if
noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Target Symptoms: Half-Life: Notable Side Effects:
• Bipolar Disorder • Decanoate is approx. • Neuroleptic-induced
• Psychotic disorders 3 weeks deficit syndrome
• Behavioral disturbances in dementias • Oral: 12-38 hours • Akathisia
• Delirium w/ Metabolism: • Drug-induced Parkinsonism
Lorazepam • CYP1A2 • Tardive dyskinesia, Tardive dystonia
Schizophrenia • CYP2D6 • Risk of potentially irreversible
• Tics and vocal utterances in • CYP3A4 involuntary dyskinetic
Tourettes Syndrome movements may increase with
• Second line treatment of severe cumulative dose and treatment
behavior in children of duration
combative explosive • Galactorrhea, Amenorrhea
hyperexcitability • Dizziness Sedation
Potency: • Dry mouth, constipation,
• High potency first-generation urinary retention, blurred
Neurotransmitters: vision
• Blocks dopamine 2 receptors, • Decreased sweating
reducing positive symptoms of • Hypotension
psychosis and possibly combative, • Tachycardia
explosive, and hyperactive behaviors • Hypertension
• Blocks dopamine 2 receptors in the • Weight gain
nigrostriatal pathway, improving
tics and other symptoms in
Tourette’s
syndrome.
